Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LUCAR G39D

Next Previous
Drug Profile

LUCAR G39D

Alternative Names: CD19xCD20 CAR-γδ T cell therapy - Legend Biotech; LUCAR-G39D

Latest Information Update: 09 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nanjing Legend Biotech
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 06 Dec 2025 Interim adverse events and efficacy data from a phase-I trial in Non-Hodgkin's lymphoma released by Legend Biotech
  • 09 May 2024 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (Parenteral)(NCT06395870)
  • 02 May 2024 Nanjing Legend Biotech plans a phase I trial for Non-hodgkin lymphoma (Second line therapy) in China in May 2024 (parenteral) (NCT06395870)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top